Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is N/A as of Tuesday, October 6, 2026.
EBITDA MARGIN
N/A
Market Cap
$21.90M
EBITDA Margin
-7.62%
TTM Avg
-5.66%
3Y Avg
-2.78%
5Y Avg
-31.67%
Market Cap
$18.82M
EBITDA Margin
-23.24%
TTM Avg
-24.75%
3Y Avg
-25.93%
5Y Avg
-17.56%
Market Cap
$24.44M
EBITDA Margin
-710238.40%
TTM Avg
-369696.29%
3Y Avg
-185511.92%
5Y Avg
-193923.76%
Market Cap
$16.58M
EBITDA Margin
-82.81%
TTM Avg
-187.23%
3Y Avg
-342.47%
5Y Avg
-369.32%
Market Cap
$16.54M
EBITDA Margin
-579.88%
TTM Avg
-374.35%
3Y Avg
-344.55%
5Y Avg
-411.92%
Market Cap
$25.48M
EBITDA Margin
-883.91%
TTM Avg
-2536.80%
3Y Avg
-2479.09%
5Y Avg
-2025.77%
Market Cap
$16.22M
EBITDA Margin
-13679.31%
TTM Avg
-8051.39%
3Y Avg
-4553.85%
5Y Avg
-5076.49%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Actuate Therapeutics Inc (ACTU) | $20.93M | N/A | N/A | N/A | N/A |
| Aytu BioPharma, Inc. (AYTU)vs › | $21.90M | -7.62% | -5.66% | -2.78% | -31.67% |
| Cosmos Health Inc. (COSM)vs › | $18.82M | -23.24% | -24.75% | -25.93% | -17.56% |
| Estrella Immunopharma, Inc. (ESLA)vs › | $18.77M | N/A | N/A | N/A | N/A |
| Atossa Therapeutics, Inc. (ATOS)vs › | $24.44M | -710238.40% | -369696.29% | -185511.92% | -193923.76% |
| Bionano Genomics, Inc. (BNGO)vs › | $16.58M | -82.81% | -187.23% | -342.47% | -369.32% |
| Dyadic International, Inc. (DYAI)vs › | $16.54M | -579.88% | -374.35% | -344.55% | -411.92% |
| ABVC BioPharma, Inc. (ABVC)vs › | $25.48M | -883.91% | -2536.80% | -2479.09% | -2025.77% |
| BioCardia, Inc. (BCDA)vs › | $16.22M | -13679.31% | -8051.39% | -4553.85% | -5076.49% |
| Allarity Therapeutics, Inc. (ALLR)vs › | $15.91M | -14633.33% | -7486.14% | -4543.27% | -3157.51% |
Gross Margin
0.0%
EBITDA Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
